Seretide Diskus 50 mikrograma+100 mikrograma u jednoj dozi, prašak inhalata, dozirani
Name | Seretide Diskus 50 mikrograma+100 mikrograma u jednoj dozi, prašak inhalata, dozirani |
---|---|
Marketing Authorisation Number | HR-H-491933173 |
Active Substance | salmeterolksinafoat flutikazonpropionat |
Composition | svaka pojedinačna inhalacija sadrži isporučenu dozu (iz nastavka za usta) od 47 mikrograma salmeterola (u obliku salmeterolksinafoata) i 92 mikrograma flutikazonpropionata što odgovara predinhalacijskoj dozi od 50 mikrograma salmeterola (u obliku salmeterolksinafoata) i 100 mikrograma flutikazonpropionata |
Pharmaceutical Form | prašak inhalata, dozirani |
Manufacturer | Glaxo Wellcome Production, Evreux, Francuska |
Marketing Authorisation Holder | GlaxoSmithKline Trading Services Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Irska |
Marketing Authorisation Date | 20.08.2021 |
MA Period of Validity | unlimited |
Classification Number | UP/I-530-09/19-02/76 |
Registration Number | 381-12-01/70-21-17 |
Prescription | na recept |
Type of prescription | ponovljivi recept |
Distribution | u ljekarni |
Advertising to general public | zabranjeno |
ATC Code | R03AK06 |
Medicinal product marketed in the Croatia | Da |
SmPC | download |
PL | download |
Public Assessment Report | download |